Vascular Health and Risk Management
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Pre-eclampsia: pathophysiology, diagnosis, and management
(34817) Total Article Views
Authors: Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M
Published Date July 2011
Volume 2011:7 Pages 467 - 474
Jennifer Uzan1, Marie Carbonnel1, Olivier Piconne1,3, Roland Asmar2, Jean-Marc Ayoubi1
1Department of Gynecology and Obstetrics, Hôpital Foch, Suresnes, France; 2Foundation Medical Research Institutes, Geneva, Switzerland; 3Department of Gynecology and Obstetrics, Hôpital Antoine Béclère, Clamart, France
Abstract: The incidence of pre-eclampsia ranges from 3% to 7% for nulliparas and 1% to 3% for multiparas. Pre-eclampsia is a major cause of maternal mortality and morbidity, preterm birth, perinatal death, and intrauterine growth restriction. Unfortunately, the pathophysiology of this multisystem disorder, characterized by abnormal vascular response to placentation, is still unclear. Despite great polymorphism of the disease, the criteria for pre-eclampsia have not changed over the past decade (systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg and 24-hour proteinuria ≥0.3 g). Clinical features and laboratory abnormalities define and determine the severity of pre-eclampsia. Delivery is the only curative treatment for pre-eclampsia. Multidisciplinary management, involving an obstetrician, anesthetist, and pediatrician, is carried out with consideration of the maternal risks due to continued pregnancy and the fetal risks associated with induced preterm delivery. Screening women at high risk and preventing recurrences are key issues in the management of pre-eclampsia.
Keywords: pre-eclampsia, epidemiology, pathophysiology, therapeutic management
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Jean Marc Ayoubi
Readers of this article also read:
- Like us on Facebook
Click the blue link above to become a part of our Facebook community.
- MLA'14 -
May 16–21, 2014
- Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
- The western diet and lifestyle and diseases of civilization
- Everolimus-eluting stents in interventional cardiology
- Transitioning from population to individualized preventive cardiology